Free Trial
Your $100 Credit Expires Tomorrow! Get MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion
Corinne Jenkins

Corinne Jenkins Analyst Performance

Vice President at The Goldman Sachs Group

Corinne Jenkins is a stock analyst at The Goldman Sachs Group focused in the medical sector, covering 6 publicly traded companies. Over the past year, Corinne Jenkins has issued 8 stock ratings, including buy, hold, and sell recommendations. While full access to Corinne Jenkins' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Corinne Jenkins' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
12 Last 4 Years
Buy Recommendations
58.33% 7 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy58.3%7 ratings
Hold33.3%4 ratings
Sell8.3%1 ratings

Out of 12 total stock ratings issued by Corinne Jenkins at The Goldman Sachs Group, the majority (58.3%) have been Buy recommendations, followed by 33.3% Hold and 8.3% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Corinne Jenkins, an analyst at The Goldman Sachs Group, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
5 companies
83.3%
Business Services
1 company
16.7%

Corinne Jenkins of The Goldman Sachs Group specializes in stock coverage within the Medical sector, with additional focus on Business Services companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
83.3%
TECHNOLOGY SERVICES
1 company
16.7%

Corinne Jenkins' Ratings History at The Goldman Sachs Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4/14/2026Boost Price Target$31.97$35.00Neutral
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
12/15/2025Boost Price Target$21.89$33.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
12/12/2025Boost Price Target$117.62$157.00Buy
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
10/21/2025Boost Price Target$30.51$30.00Neutral
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
10/17/2025Lower Price Target$111.18$139.00Buy
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
9/24/2025Boost Price Target$96.10$138.00Buy
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
9/18/2025Boost Price Target$15.06$24.00Buy
Geron Corporation stock logo
GERN
Geron
7/10/2025Initiated Coverage$1.44$1.00Sell